AQST Aquestive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%
Returns
ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $44.55M | $57.56M |
| Cost of revenue | $18.55M | $17.87M |
| Gross profit | $25.99M | $39.69M |
| R&D expense | $17.19M | $20.28M |
| SG&A expense | $79.85M | $50.18M |
| Operating income | -$71.05M | -$30.77M |
| Interest expense | $11.12M | $11.12M |
| Pretax income | -$83.78M | -$44.15M |
| Income tax | $0 | -$14,000 |
| Net income | -$83.78M | -$44.14M |
| EBITDA | -$70.50M | -$30.05M |
| EPS (basic) | -0.78 | -0.51 |
| EPS (diluted) | -0.78 | -0.51 |
| Weighted avg. shares (diluted) | 106.93M | 86.73M |
| Balance sheet | ||
| Cash & equivalents | $121.17M | $71.55M |
| Receivables | $17.76M | $7.34M |
| Inventory | $6.17M | $6.04M |
| Current assets | $149.27M | $88.22M |
| PP&E, net | $3.89M | $3.80M |
| Intangibles | $0 | $0 |
| Total assets | $160.43M | $101.42M |
| Current liabilities | $47.61M | $18.86M |
| Short-term debt | $9.99M | — |
| Long-term debt | $27.52M | $32.50M |
| Total debt | $37.51M | $32.50M |
| Total liabilities | $194.09M | $161.58M |
| Shareholders' equity | -$33.66M | -$60.16M |
| Net debt | -$83.66M | -$39.05M |
| Shares outstanding | 122.04M | 91.41M |
| Cash flow statement | ||
| Operating cash flow | -$52.43M | -$35.76M |
| Capital expenditure | $562,000 | $159,000 |
| Free cash flow | -$52.99M | -$35.92M |
| Investing cash flow | -$562,000 | -$159,000 |
| Financing cash flow | $102.62M | $83.59M |
| Depreciation & amortization | $548,000 | $718,000 |
| Stock-based compensation | $7.62M | $7.10M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.